CTOs on the Move

Aerin Medical

www.aerinmedical.com

 
Aerin`s advanced treatment platform utilizes low-power radiofrequency energy to remodel nasal soft tissues and address the underlying cause of nasal congestion. Treatment styluses are uniquely designed for each procedure and deliver energy to the target tissue surface without the need for incisions or tissue penetration.Proprietary algorithms ensure that targeted tissues are exposed to carefully controlled energy resulting in treatment temperatures that are below the tissue ablation range. The technology is protected by a comprehensive patent estate consisting of both method and design patents.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Aerin Medical raised $15M on 12/13/2017
Aerin Medical raised $48M on 08/17/2020
Aerin Medical raised $38.8M on 05/03/2022

Similar Companies

Argene SA

Argene SA is a Massapequa, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Neurotrack

Neurotrack is a digital health company dedicated to the development of non-invasive cognitive health assessment tools that will enable earlier and more effective evaluation of patients who may be at risk for cognitive decline, and help advance research of treatments for cognitive diseases, including Alzheimer`s.

Odyssey Research Services

Odyssey Research Services is a Bismarck, ND-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Palvella Therapeutics

Palvella Therapeutics was founded with the single-minded goal of serving individuals suffering from serious rare genetic diseases with no approved treatments.

Entrada Therapeutics

Entrada Therapeutics is a biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines, Endosomal Escape Vehicles (EEV™), to engage intracellular targets that have long been considered inaccessible and undruggable. The Company`s EEV therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues with an improved therapeutic index. Through its proprietary, highly versatile and modular EEV Platform, Entrada is building a robust development portfolio of oligonucleotide-, antibody- and enzyme-based programs for the potential treatment of neuromuscular disease, immunology, oncology and diseases of the central nervous system.